Gastric cancer is the sixth most common cancer and an important cause of cancer-related deaths worldwide [1]. According to cancer statistics in Turkey, gastric cancer is the 5th most common cancer both in men and women [2]. Genetic and environmental risk factors are responsible for the etiology of gastric cancer. Among those smoking, alcohol usage, smoked and salted foods, helicobacter pylori infection, pernicious anemia, chronic atrophic gastritis, intestinal metaplasia, previous gastric operations, peutz-jeghers syndrome, li-fraumeni syndrome and hereditary diffuse gastric cancer syndrome are the most important ones [3–6]. International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) TNM stage is the most important determinant of prognosis after surgery [7]. Studies reported that there are also many other prognostic factors that affect survival, such as lymphovascular invasion, grade, resection type and performance status [8, 9].
Although nowadays remarkable progress has been made in gastric cancer treatment, gastrectomy with regional lymphadenectomy still remains the primary treatment for the resectable disease. Surgical resection alone with no pre- or postoperative treatment provides a five-year overall survival (OS) rate of approximately 20–30% [10, 11]. For potentially resectable patients, several randomized trials indicated a significant survival benefit of different adjuvant treatment approaches in comparison to surgery alone [11–15]. Adjuvant chemoradiotherapy is one of these approaches where survival benefit was demonstrated in the landmark SWOG 9008/INT-0116 trial [12]. Perioperative (preoperative plus postoperative) chemotherapy is another option for these patients whose survival benefit has been demonstrated in the MAGIC trial [11]. Nowadays, adjuvant treatment decision is mainly made according to the TNM stage, performance status, comorbidities of the patient, and toxicities of adjuvant chemotherapy and radiotherapy.

We aimed to investigate the factors that affect the survival of gastric cancer patients treated in our center and compare our results with the literature.

MATERIALS AND METHODS

Patients with pathological diagnosis of gastric cancer who were operated and either followed-up or received adjuvant therapy after operation or who were inoperable and treated with definitive chemoradiotherapy in our center between 2005 and 2016 were evaluated retrospectively in this study. Patients were staged according to the AJCC staging system (7th edition). All of the patients were older than 18 years, and their performance status scores were ≤2 according to the ECOG (Eastern Cooperative Oncology Group) scoring system.

Patient Characteristics

In this study, 232 out of 345 patients were male, while 113 out of 345 patients were female. The median age was 57.1. While 11 (3%) patients were locally advanced and underwent endoscopic biopsy only, total gastrectomy was performed in 166 patients (48%) and subtotal gastrectomy was performed in 168 patients (49%). Regarding the lymph node status of the patients, 258 patients (75%) had nodal metastases, while 76 patients (22%) were confirmed to be node-negative based on pathologic examination. According to staging, 50 out of 345 patients were stage I, 94 out of 345 patients were stage II, and 201 out of 345 patients were stage III. Perineural invasion was identified in 203 (59%) patients, and lymphovascular invasion was identified in 238 (69%) patients. Histologic grades of the patients were as follows, 41 patients had grade 1 (12%), 107 patients had grade 2 (31%), and 186 patients had grade 3 (54%) disease. The patient characteristics are summarized in Table 1.

Treatment and Follow-up

Two hundred twenty-one patients (64%) presenting with serosal or adjacent visceral organ invasion or with involved lymph nodes were considered suitable for adjuvant chemoradiotherapy. The adjuvant treatment plan was similar to the intergroup-0116 trial presented in 2001 by MacDonald et al. [12]. The radiation was administered by 1.8 Gy fractions per day, five days per week, either 45 Gy in 25 fractions in 180 patients or 50.4 Gy in 28 fractions in 28 patients. Thirteen patients could not complete 45 Gy due to toxicity. Radiation therapy was planned by either three-dimensional (3D) conformal technique in 165 patients or two-dimensional (2D) technique in 56 patients. All of the patients received bolus or infusional 5-fluorouracil, one cycle before and one cycle after radiation treatment. Different concomitant chemotherapy schemes were used, including either bolus fluorouracil and leucovorin, or infusional fluorouracil or oral capecitabine. Treatment characteristics of the patients are summarized in Table 2. While bolus fluorouracil (400 mg/m²/day) and leucovorin (20 mg/m²/day) were administered at the first four and the last three days of radiotherapy, infusional fluorouracil (225 mg/m²/day) was given continuously throughout the radiotherapy, and oral capecitabine (825 mg/m²/twice a day) as well.

In the first two years after surgery, patients were followed up regularly with three monthly intervals and then every six months in the third year and annually thereafter. During the follow-up visits, patients underwent physical examination, complete blood tests, chest radiography and computerized tomography or magnetic resonance imaging as clinically indicated. Upper gastrointestinal endoscopy was used to verify locoregional recurrence.

Statistical Analysis

Recurrence-free survival (RFS) is defined as the time span from the date of diagnosis to the date of histologically or radiologically confirmed the first relapse, and overall survival (OS) is defined as the time span from
the date of diagnosis to the date of death or last control date of the patients. The survival analysis was calculated using the Kaplan–Meier method, and the log-rank test was used for the univariate analysis. A Cox proportional hazard model was utilized for multivariate analysis in order to determine independent prognostic factors. All the tests were two-sided, and a p-value of <0.05 was considered to be statistically significant. Statistical analyses were performed using The Statistical Package for Social Sciences (SPSS 17, Chicago, IL, USA). Informed consent has been obtained from all the patients. The

**Table 1.** Demographic and clinicopathologic characteristics of the patients

| Characteristics                  | n  | %  |
|----------------------------------|----|----|
| Gender                           |    |    |
| Male                             | 232| 67 |
| Female                           | 113| 33 |
| Age (yr), mean±SD                | 57.1±11.5 |    |
| Tumor location                   |    |    |
| Gastroesophageal junction        | 11 | 3  |
| Fundus, cardia                   | 85 | 25 |
| Corpus                           | 100| 29 |
| Antrum, pylorus                  | 149| 43 |
| Surgical resection type          |    |    |
| Total gastrectomy                | 166| 48 |
| Subtotal gastrectomy             | 168| 49 |
| Resectable                       | 11 | 3  |
| Tumor size                       |    |    |
| <5 cm                            | 139| 41 |
| 5–10 cm                          | 170| 49 |
| >10 cm                           | 36 | 10 |
| Lymphovascular invasion          |    |    |
| Yes                              | 238| 69 |
| No                               | 96 | 28 |
| Unknown                          | 11 | 3  |
| Perineural invasion              |    |    |
| Yes                              | 203| 59 |
| No                               | 131| 38 |
| Unknown                          | 11 | 3  |
| Grade                            |    |    |
| I                                | 41 | 12 |
| II                               | 107| 31 |
| III                              | 186| 54 |
| Unknown                          | 11 | 3  |
| Surgical margin                  |    |    |
| Negative                         | 294| 85 |
| Positive                         | 40 | 12 |
| Inoperable                       | 11 | 3  |
| T-Stage                          |    |    |
| T1/T2                            | 98 | 39 |
| T3/T4                            | 247| 71 |
| N-Stage                          |    |    |
| N0                               | 76 | 22 |
| N1                               | 68 | 20 |
| N2                               | 90 | 26 |
| N3a                              | 74 | 21 |
| N3b                              | 26 | 8  |
| NX                               | 11 | 3  |
| TNM Stage                        |    |    |
| IA                               | 10 | 3  |
| IB                               | 40 | 12 |
| IIA                              | 44 | 13 |
| IIB                              | 50 | 14 |
| IIIA                             | 70 | 20 |
| IIIIB                             | 62 | 18 |
| IIIIC                             | 69 | 20 |

**Table 2.** Treatment characteristics of the patients

| Characteristics                      | n  | %  |
|--------------------------------------|----|----|
| Adjuvant radiotherapy                |    |    |
| Yes                                  | 221| 64 |
| No                                   | 124| 36 |
| Radiation technique                  |    |    |
| Two-dimensional radiotherapy         | 56 | 25 |
| Three-dimensional radiotherapy       | 165| 75 |
| Radiation dose                       |    |    |
| <45 Gy                               | 13 | 6  |
| 45 Gy                                | 180| 81 |
| 50.4 Gy                              | 28 | 13 |
| Concomitant chemotherapy             |    |    |
| Bolus 5-FU*                          | 107| 48 |
| Infusional 5-FU                      | 78 | 35 |
| Oral Capecitabine                    | 36 | 17 |

*5-FU: 5-fluorouracil.

**Table 3.** Overall survival according to pathological stage

| Stage  | Patients (n) | 1 year survival (%) | 3 years survival (%) | 5 years survival (%) | Median survival (month) |
|--------|--------------|----------------------|----------------------|----------------------|-------------------------|
| IA     | 10           | 100                  | 90                   | 90                   | Not reached             |
| IB     | 40           | 95                   | 89                   | 85                   | Not reached             |
| IIA    | 44           | 95                   | 83                   | 74                   | 71                      |
| IIB    | 50           | 94                   | 73                   | 62                   | 66                      |
| IIIA   | 70           | 89                   | 54                   | 48                   | 40                      |
| IIIIB  | 62           | 82                   | 44                   | 28                   | 30                      |
| IIIIC  | 69           | 50                   | 24                   | 13                   | 12                      |

SD: Standard deviation.
local Ethical Committee of our hospital approved the study in concordance with the declaration of Helsinki (2018/514/136/1).

RESULTS

Median follow up time was 34 months (4–156 months). Median overall survival (OS) was 51 months and OS rates for 1st, 3rd and 5th years were 85%, 55% and 45%, respectively. Median overall survival has not been reached for stage IA and IB disease. Overall survival according to pathological stages is summarized in Table 3 and Figure 1. Median recurrence-free survival was 35 months and RFS rates for 1st, 3rd and 5th years were 72%, 49% and 38%, respectively. While locoregional recurrence was detected in 56 patients (16.2%), distant metastasis was observed in 147 patients (42.6%). At the time of analysis, 10 patients were still alive despite recurrence, and 205 patients died related to gastric cancer.

According to the univariate analysis, tumor size (p<0.001), T stage (p<0.001), N stage (p<0.001), TNM stage (p<0.001), grade (p<0.001), and the presence of lymphovascular invasion (p=0.005) were found as factors that have an effect on survival. Prognostic factors affecting survival according to univariate analysis are summarized in Table 4. According to the multivariate analysis, the T stage was determined to be an independent prognostic factor for overall survival and there was a threefold increase in mortality in patients with T4 stage as compared with the patients with T1 stage (p=0.001). The nodal stage was found as another independent prognostic factor for overall survival and mortality was increased by 4.2 fold in patients with N3 category and 2.7 fold in patients with N2 category when compared to the patients with N0 category (p<0.001). Hazard ratios for overall survival depending on the T stage and N stage are summarized in Table 5.

DISCUSSION

The incidence and mortality rates of gastric cancer differ throughout the world [16]. Epidemiological studies demonstrate a decrease in gastric cancer incidence [17]. While gastric cancer incidence has decreased in the last decades in Turkey [18], its incidence is still highest among the Middle East countries [19]. Gastric cancer

---

**Table 4. Prognostic factors affecting survival according to univariate analysis**

| Univariate analysis       | p      |
|---------------------------|--------|
| Tumor size                | <0.001 |
| T-stage                   | <0.001 |
| N-stage                   | <0.001 |
| Lymphovascular invasion   | 0.005  |
| Grade                     | <0.001 |
| TNM stage                 | <0.001 |

**Table 5. Prognostic factors affecting survival according to multivariate analysis**

| p      | HR    | 95% CI   |
|--------|-------|----------|
| T Stage<0.001 |       |          |
| T1     |       |          |
| T2     | 0.33  | 1.44     | 0.69–2.99 |
| T3     | 0.07  | 1.88     | 0.95–3.74 |
| T4     | 0.001 | 3.01     | 1.55–5.87 |
| N Stage<0.001 |       |          |
| N0     |       |          |
| N1     | 0.2   | 1.43     | 0.83–2.47 |
| N2     | <0.001| 2.7      | 1.67–4.36 |
| N3     | <0.001| 4.12     | 2.58–6.55 |

HR: Hazard ratio; CI: Confidence interval.

---

**Figure 1.** Overall survival according to the stage.
is observed more frequently in males than in females [17]. Our study also demonstrated the female to male ratio as 1/2. While the incidence of proximal tumors is increasing in the western world, distal tumors continue to be predominant in Japan [20]. In Turkey, most of the cases are diagnosed at an advanced stage, and majority is located distally [21]. In our study, 72% of the patients presented with distally located tumors. Lymphovascular invasion was found to be an independent prognostic factor as in most of the studies [22–24]. Lymphovascular invasion was observed in 69% of our patients with very high frequency in contrast to the rates ranging between 31.9–44.3% reported in the literature [22–24].

Surgery is a major curative treatment. Despite the improvements in surgical techniques, surgery alone with no pre or postoperative treatment provides a fair overall survival. Recent randomized studies in resectable gastric cancer patients comparing surgery with or without preoperative chemotherapy or comparing D1 versus D2 resection demonstrated overall survival between 20–30% with surgery alone [10, 11]. Survival rates vary according to the T and N stage, being around 85–90% in T1 tumors and around 15–20% in T4 tumors and node-positive patients [25]. Loco-regional recurrence rates are important concern in resected patients [25]. Therefore, a multi-modal approach is necessary to improve surgical results. Adjuvant chemotherapy alone or concomitant with radiotherapy, or perioperative chemotherapy are the most studied and effective treatment approaches.

Adjuvant chemoradiotherapy is the preferred treatment option for resected gastric cancer patients with less than D2 lymph node dissection [26]. The landmark trial which demonstrated the role of adjuvant chemoradiotherapy is the INT0116 trial. In this study, including 281 non-metastatic gastric cancer patients, adjuvant radiotherapy concomitant with 5-fluorouracil/leucovorin were compared with observation after surgery. Three-years OS and RFS were found to be significantly better in adjuvant chemoradiotherapy arm, 50% versus 41% and 48% versus 31%, respectively, after five years of follow-up [12]. When we compared our results with the INT0116 study, with a median follow-up of 34 months, we found similar 3-years OS and RFS rates, 55% and 49%, respectively. Another study from Turkey comprising 637 patients treated with adjuvant chemoradiotherapy after curative resection demonstrated a median overall survival of 43.7 months and a median recurrence-free survival of 36.6 months [27]. The OS rates were 80%, 52%, and 38%, while the RFS rates were 75%, 48%, and 34% at 1, 3 and 5-years, respectively. Although recurrence-free survivals were found to be similar in both studies, the overall survival time in our study was better and this was probably due to the inclusion of the early-stage patients. In our study, overall survivals range between 85 to 90% for stage I disease, range between 62–74% for stage II disease, and between 13–48% for stage III disease as summarized in Table 3. Tumor penetration through the gastric wall, and the presence of lymph node involvement have been shown as two important prognostic factors in the literature [26, 28, 29]. Hochwald and Gunji et al. [29, 30] demonstrated that the number of involved nodes had a negative impact on RFS and OS. In a study from Japan [28], the anatomic distribution of involved lymph nodes was found to have prognostic importance. Marchet et al. [31] demonstrated the importance of extent of the lymph node dissection and the number of metastatic lymph nodes. In our study, N stage, which represents the number of metastatic lymph nodes, was found as a prognostic factor for OS both in univariate and multivariate analysis.

Dockerty [32] reported that when the tumor was confined to the mucosa, the 5-year survival rate was 100%, and when the tumor invades below mucosa, the 5-year survival rate was 61%, and it was 44% when the tumor invaded the entire stomach wall. We found the T stage as a prognostic factor for survival both in univariate and multivariate analysis. The five-year survival rate was 84.3% in T1 tumors, 64.8% in T2 tumors, 48.9% in T3 tumors, and 29.2% in T4 tumors.

In the Turkish study mentioned above [27], while tumor grade, T stage, N stage, surgical resection type and surgical margin were reported as prognostic factors for RFS and OS in the univariate analysis, T stage, N stage and surgical margin were reported as significant factors for OS in the multivariate analysis. In our study, while we found the T and N stage, tumor size, stage groups, tumor grade and presence of lymphovascular invasion as prognostic factors for OS in univariate analysis, only T and N stage were detected as independent prognostic factors for OS in the multivariate analysis.

While adjuvant chemoradiotherapy provided a survival benefit in resected gastric cancer, certain authors have questioned the role of this adjuvant treatment modality, especially in patients who underwent D2 lymph node dissection, and in patients who received perioperative or postoperative chemotherapy. Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) trial compared...
adjunct chemotherapy with or without radiotherapy in D2 lymph node dissected patients [33]. In subgroup analysis, postoperative chemoradiotherapy provided a better disease-free survival with in comparison to postoperative chemotherapy alone in node-positive and intestinal-type gastric cancer patients. However, the role radiotherapy was not evident in the whole group [30]. The ongoing ARTIST II trial will elucidate if there is any benefit of adding postoperative radiotherapy to chemotherapy in D2 lymph node dissected patients when there are lymph node metastases [34].

Our study has several drawbacks. This study was retrospective; and this study included early-stage disease with no postoperative treatment, and included 2-dimensional radiotherapy techniques. Technical advances in radiotherapy, together with effective adjuvant chemotherapy combinations, will improve the treatment results obtained with surgery.

Conclusion
Our results have demonstrated that postoperative chemoradiotherapy in resected gastric cancer in the Turkish population is feasible and provides similar survival results comparable to the studies reported in the literature. Nodal involvement and tumor invasion through the gastric wall are two independent prognostic factors found to have an effect on overall survival.

Ethics Committee Approval: Kartal Dr. Lutfi Kırdar Training and Research Hospital Clinical Research Ethics Committee of approved the study in concordance with the declaration of Helsinki (date: 28.08.2018, number: 2018/514/136/1).

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – GY; Design – DT; Supervision – GY; Materials – BD; Data collection and/or processing – MP; Analysis and/or interpretation – GY; Literature review – BD; Writing – GY; Critical review – DT.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. TC Sağlık Bakanlığı Halk Sağlığı Kurumu. Türkiye Kanser İstatistikleri Raporu 2017. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2014-RAPOR_uuzuun.pdf. Accessed Mar 19, 2020.
3. Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med 2013;11:58.
4. Chou HH, Kuo CJ, Hsu JT, Chen TH, Lin CJ, Tseng JH, et al. Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg 2013;205:623–30.
5. Lagergren J, Bergström R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340–6.
6. Carr JS, Zafar SF, Saha N, Khuri FR, El-Raies BF. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer 2013;44:143–51.
7. Zhang J, Zhou Y, Jiang K, Shen Z, Ye Y, Wang S. Evaluation of the seventh AJCC TNM staging system for gastric cancer: a meta-analysis of cohort studies. Tumour Biol 2014;35:8525–32.
8. Hermanek P, Wittekind C. News of TNM and its use for classification of gastric cancer. World J Surg 1995;19:491–5.
9. Bu Z, Zheng Z, Li Z, Zhang L, Wu A, Wu X, et al. Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients. Tumour Biol 2013;34:1005–12.
10. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joyeau V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522–30.
11. Cunningham D, Allum WH, Steenwinckel PR, Thompson JN, Van de Velde CJ, Nicolson M, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable oesophago-gastric cancer. N Engl J Med 2006;355:11–20.
12. McLeod RS, Smalley SR, Benedetti J, Hundal SA, Estes NC, Stemmerrmann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.
13. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) – report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:299–34.
14. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001;84:878–80.
15. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebret G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–21.
16. Avital I, Pisters PW, Kelsen DP, Willet GC. Cancer of the stomach. In: DeVita VT, Lawrence T, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2011. p. 924–54.
17. Ferlay F, Bray F, Pisani P, Parkin DM. Globocan 2002 cancer incidence, mortality and prevalence worldwide. IARC Cancer. Base No 5. Lyon: IARC Press; 2004.
18. Fidanci C, Eser SY, Parkin DM. Incidence in Izmir in 1993–1994: first report from Izmir Cancer Registry. Eur J Cancer 2001;37:83–92.
19. Yalcin S. Gastric cancer in Turkey—a bridge between west and east. Gastrointest Cancer Res 2009;3:29–32.
20. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127–64.
21. Demir G, Büyükünal E, Kızilkılıc E, Özgüroğlu M, Mandel N, Demirelli F, et al. Gastric cancer in Turkey: a single center experience of 683 cases. J Clin Oncol 2004;22.
22. Li P, He HQ, Zhu CM, Ling YH, Hu WM, Zhang XK, et al. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer. 2015;15:370.
23. del Casar JM, Corte MD, Alvarez A, Garcia I, Bongera M, González LO, et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol 2008;134:153–61.
24. Kim JH, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer. J Surg Res 2010;162:177–83.
25. Gunderson LL. Gastric cancer—patterns of relapse after surgical resection. Semin Radiat Oncol 2002;12:150–61.
26. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279–85.
27. Kucukoner M, Isikdogan A, Arpaci E, Bilici M, Uncu D, Cetin B, et al. Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology. Hepatogastroenterology 2012;59:2343–7.
28. Okajima K. Prognostic factors of gastric cancer patients—a study by univariate and multivariate analysis [in Japanese, with English abstract]. Jpn J Gastroenterol Surg 1997;30:700–11.
29. Hochwald SN, Kim S, Klimstra DS, Brennan MF, Karpeh MS. Analysis of 154 actual five-year survivors of gastric cancer. J Gastrointest Surg 2000;4:520–5.
30. Gunji Y, Suzuki T, Hori S, Hayashi H, Matsubara H, Shimada H, et al. Prognostic significance of the number of metastatic lymph nodes in early gastric cancer. Dig Surg 2003;20:148–53.
31. Marchet A, Mocellin S, Ambrosi A, de Manzoni G, Di Leo A, Marrelli D, et al; Italian Research Group for Gastric Cancer Study (GIRCG). The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol 2008;34:159–65.
32. Dockerty MB. Pathology aspects of primary malignant neoplasms of stomach. In: ReMine WH, Priestly JT, Berkson J, editors. Cancer of the Stomach. Philadelphia: WB Saunders; 1964. p. 173.
33. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268–73.
34. Kang WK. Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma: The ARTIST II Trial (ARTIST-II) Available at: https://clinicaltrials.gov/ct2/show/NCT01761461. Accessed Mar 17, 2020.